ClinicalTrials.gg
SuspendedNCT07636161Updated Sep 28, 2026

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

A Phase 4 interventional study of Eroxon® and tadalafil in Type 2 Diabetes and Type 2 Diabetes (T2DM), sponsored by University of Miami. Suspended at 1 site in United States. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Miami · Phase 4, Interventional, and Treatment

How we know

Why this study was suspended
The sponsor has communicated that they may no longer fund this research study. Pending final confirmation if the study will be closed.
Updated Sep 28, 2026Now SuspendedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
2,238th of 2,961
30 · median 90
Started
2026
with 157 others
Phase 4
300 of 3,308
19 open now
Registered
3,249th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,238th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 158 that started in 2026, is one of 300 in phase 4, and was the 3,249th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 40 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to look at whether Eroxon® gel when used together with tadalafil, may help improve erectile function in men ages 18 to 40 who have type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
  • Type 2 Diabetes (T2DM)
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male sex at birth
  • Age 18-40 years
  • Diagnosis of type 2 diabetes mellitus
  • Diagnosis of erectile dysfunction
  • Currently prescribed tadalafil
  • Have a sexual partner willing to complete a survey
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Severe psychiatric illness that would impair participation
  • Use of nitrates or to sexual activity
  • Known allergy to Eroxon® gel components
  • Participation in another interventional sexual health study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Standard of Care (Tadalafil) + Eroxon® Gel Group

    Participants assigned to this arm will continue to use tadalafil as prescribed per standard of care treatment and will also be instructed to use Eroxon® gel prior to each sexual encounter throughout the 12-week study period.

    Device: Eroxon® · Drug: tadalafil

  • Active comparator
    Tadalafil (Control) Group

    Participants assigned to this arm will continue their standard-of-care treatment with tadalafil as prescribed. No study-specific changes will be made to their routine clinical management.

    Drug: tadalafil

Interventions

  • DeviceEroxon®

    Participants will receive a 12-week supply of Eroxon® and will be instructed to apply the gel prior to each sexual encounter as directed at enrollment.

  • Tadalafil is administered as standard of care at dose and schedule determined by the treating clinician.

06

What researchers measure

Primary outcomes

  1. Change in Erectile Functioning

    Erectile function assessed using the International Index of Erectile Function-5 (IIEF-5), a validated 5-item patient-reported questionnaire. Total scores range from 5 to 25, with higher scores indicating better erectile function.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Patient Adherence

    Patient adherence assessed using the Medication Adherence Report Scale-5 (MARS-5), a validated five-item self-report questionnaire measuring both intentional and unintentional non-adherence. Each item is scored on a 5-point Likert scale, with total scores ranging from 5 to 25, and higher scores indicating better adherence.

    Time frame: Baseline to Week 12

  2. Change in Partner Acceptability

    Partner acceptability assessed using the Sexual Life (ISL) scale, a validated 11-item questionnaire evaluating satisfaction and acceptability related to sexual activity. Each item is scored on a 5-point Likert scale, with total scores ranging from 5 to 25, with higher scores indicating greater partner satisfaction and acceptability.

    Time frame: Baseline to Week 12

07

Study locations

1 site
  • Don Soffer Clinical Research Building
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 9, 2026
StartEst.
Oct 2026was Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Suspended The sponsor has communicated that they may no longer fund this research study. Pending final confirmation if the study will be closed.
changed Sep 28, 2026
Start date
Sep 2026→Oct 2026
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Suspended
    Why stopped The sponsor has communicated that they may no longer fund this research study. Pending final confirmation if the study will be closed.
    Start date Sep 2026→Oct 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07636161
Collaborators
Sexual Medicine Society of North America Inc.
Responsible party
Sonjia Kenya (Professor of Professional Practice, University of Miami) — Principal investigator
First posted
Jun 9, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Sonjia Kenya, E.D
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion